BlackRock, Inc. 13D and 13G filings for Corcept Therapeutics Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-22 3:52 pm Purchase |
2023-12-31 | 13G | Corcept Therapeutics Incorporated CORT |
BlackRock Inc. BLK |
16,407,696 15.900% |
60,313 (+0.37%) |
Filing |
| 2023-01-26 08:52 am Unchanged |
2022-12-31 | 13G | Corcept Therapeutics Incorporated CORT |
BlackRock Inc. BLK |
16,347,383 15.200% |
0 (Unchanged) |
Filing |
| 2023-01-20 3:00 pm Purchase |
2022-12-31 | 13G | Corcept Therapeutics Incorporated CORT |
BlackRock Inc. BLK |
16,347,383 15.200% |
1,299,390 (+8.63%) |
Filing |
| 2022-01-28 1:54 pm Sale |
2021-12-31 | 13G | Corcept Therapeutics Incorporated CORT |
BlackRock Inc. BLK |
15,047,993 13.000% |
-498,531 (-3.21%) |
Filing |
| 2021-01-26 2:22 pm Sale |
2020-12-31 | 13G | Corcept Therapeutics Incorporated CORT |
BlackRock Inc. BLK |
15,546,524 13.400% |
-373,562 (-2.35%) |
Filing |